Huntington's Disease Treatment Market Key Players: Hetero, Lupin, Hikma Pharmaceuticals PLC, And Dr. Reddy’s Laboratories Ltd.
Huntington's Disease
Treatment Industry Overview
The global
huntington’s disease treatment market size was valued at USD 362.0 million in
2021 and is expected to expand a compound annual growth rate (CAGR) of 19.6%
from 2022 to 2030. The expected label expansion of Ingrezza for treating chorea
associated with Huntington’s disease, high burden of HD in western countries,
and strong product pipeline of disease-modifying therapies are anticipated to
be major drivers for the market.HD roughly affects 30,000 people in North
America, with a prevalence of 5.7 per 100,000 people. HD in children is
considerably rarer, accounting for about 5% to 10% of all cases. It affects up
to 10 out of 100,000 people in Europe.
Huntington's Disease (HD) is a progressive neurological
condition caused by CAG expansions in the Huntingtin (Htt) gene. It affects one
out of every 10,000 people in the United States. Healthy people have less than
35 CAG repetitions, whereas HD patients have CAG expansions ranging from 36 to
200. The prevalence varies by more than ten-fold between geographical
locations, which can be related to variations in case ascertainment and
diagnostic criteria. The Asian population has consistently had a lower
prevalence, while Europe, North America, and Australia have a higher
prevalence. Several small molecules in clinical development are focused on
using immunomodulatory drugs to target the overactive immune system in HD.
Gather more insights about the market drivers, restrains
and growth of the Global
Huntington's Disease Treatment market
Annexon, Inc. is engaged in the development of ANX005-an
experimental monoclonal antibody that targets abnormal C1q activity in
complement-mediated neurodegenerative diseases, such as HD. This innovative
medication is administered intravenously (IV) and is meant to suppress C1q and
the complete classical complement system. In November 2020, the company
initiated a phase 2 clinical trial of ANX005 for treating HD patients. Stem
cell therapy is also generating interest as a
potential treatment for HD. Currently, Cellavita, in collaboration with
AzidusPharma, is investigating stem cell therapy, CELLAVITA-HD in phase 2/ 3
ADORE-DH trial.
However, drug development for HD has faced
significant obstacles as several therapies have failed to demonstrate efficacy
or were associated with significant toxicity. In March 2021, F. Hoffmann-La
Roche Ltd. discontinued the dosing in the phase III GENERATION HD1 study of
tominersen in manifest HD. The conclusion was made on the basis of findings of
an unblinded Independent Data Monitoring Committee's (iDMC) preplanned
examination of data from the phase III research. During analysis of this data,
no new or developing safety signals for tominersen were discovered.COVID-19
pandemic has had a slight negative impact on the market for Huntington’s
disease treatment. However, the delays in conducting clinical
trials due to the pandemic
can delay the entry of pipeline candidates into the market.
Browse through Grand View
Research's Pharmaceuticals
Industry Research Reports.
·
Enzyme Replacement Therapy Market -
The global enzyme replacement therapy market size was valued at USD 6.74
billion in 2018 and is expected to grow at a compound annual growth rate (CAGR)
of7.7% from 2019 to 2026. The rising availability of enzyme replacement
therapies, increasing awareness, and less stringent guidelines for rare
diseases are key factors driving market potential.
·
Skeletal Dysplasia Market - The
global skeletal dysplasia market size was valued at USD 2.5 billion in 2018 and
is expected to exhibit a CAGR of 4.0% over the forecast period. Skeletal
dysplasia includes around 400 conditions affecting bone development, including
cartilage growth and neurological functioning.
Huntington’s Disease Treatment Market
Segmentation
Grand View
Research has segmented the global Huntington’s disease treatment market on the
basis of treatment and region:
Huntington’s Disease
Treatment Outlook (Revenue, USD Million, 2017 - 2030)
·
Symptomatic
Treatment
·
Disease
Modifying Therapies
Huntington’s
Disease Treatment Regional Outlook (Revenue, USD Million, 2017 - 2030)
·
North America
·
Europe
·
Asia Pacific
·
Latin America
·
Middle East & Africa (MEA)
Market Share Insights
·
September
2021: NeuExcell Therapeutics Inc entered into a partnership with Spark
Therapeutics, Inc. (F. Hoffmann La Roche Ltd. owned subsidiary) for the
development of gene therapy for treating HD patients. Under the terms of the
agreement, NeuExcell Therapeutics is entitled to receive upfront license fees,
R&D, and sales milestone payments of up to approximately USD 190 million
and additional product royalties.
·
May 2020:
Teva Pharmaceutical Industries Ltd. received NMPA approval for Austedo in China
for the treatment of chorea associated with HD. China is the second country
after the U.S. to approve AUSTEDO. This geographic expansion of the company is
expected to provide a larger patient base and revenue growth.
Key Companies
profiled:
Some of the prominent players in the Huntington’s disease
treatment market include:
·
H. Lundbeck A/S
·
Teva Pharmaceutical Industries Ltd.
·
Bausch Health Companies Inc.
·
Hetero
·
Lupin
·
Hikma Pharmaceuticals PLC
·
Dr. Reddy’s Laboratories Ltd.
·
Sun Pharmaceutical Industries Ltd.
Order
a free sample PDF of the Huntington's
Disease Treatment Market Intelligence Study, published by Grand View
Research.
About
Grand View Research
Grand View Research,
U.S.-based market research and consulting company, provides syndicated as well
as customized research reports and consulting services. Registered in
California and headquartered in San Francisco, the company comprises over 425
analysts and consultants, adding more than 1200 market research reports to its
vast database each year. These reports offer in-depth analysis on 46 industries
across 25 major countries worldwide. With the help of an interactive market
intelligence platform, Grand View Research Helps Fortune 500 companies and
renowned academic institutes understand the global and regional business
environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist,
USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Comments
Post a Comment